Last reviewed · How we verify
treatment in cavitary pulmonary aspergillosis
treatment in cavitary pulmonary aspergillosis is a Small molecule drug developed by Post Graduate Institute of Medical Education and Research, Chandigarh. It is currently FDA-approved for Cavitary pulmonary aspergillosis.
This is a treatment regimen for cavitary pulmonary aspergillosis, likely combining antifungal agents to eliminate Aspergillus fungal infection in lung cavities.
This is a treatment regimen for cavitary pulmonary aspergillosis, likely combining antifungal agents to eliminate Aspergillus fungal infection in lung cavities. Used for Cavitary pulmonary aspergillosis.
At a glance
| Generic name | treatment in cavitary pulmonary aspergillosis |
|---|---|
| Sponsor | Post Graduate Institute of Medical Education and Research, Chandigarh |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Cavitary pulmonary aspergillosis is a chronic fungal infection of the lungs caused by Aspergillus species, often requiring combination antifungal therapy. Treatment typically involves azoles (such as itraconazole or voriconazole) as first-line agents, sometimes combined with amphotericin B or other antifungals, and may include surgical intervention for large cavitary lesions. The specific drug formulation from PGIMER is not publicly detailed in standard pharmaceutical databases.
Approved indications
- Cavitary pulmonary aspergillosis
Common side effects
- Hepatotoxicity
- Nephrotoxicity
- Gastrointestinal disturbances
- Infusion-related reactions
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- treatment in cavitary pulmonary aspergillosis CI brief — competitive landscape report
- treatment in cavitary pulmonary aspergillosis updates RSS · CI watch RSS
- Post Graduate Institute of Medical Education and Research, Chandigarh portfolio CI
Frequently asked questions about treatment in cavitary pulmonary aspergillosis
What is treatment in cavitary pulmonary aspergillosis?
How does treatment in cavitary pulmonary aspergillosis work?
What is treatment in cavitary pulmonary aspergillosis used for?
Who makes treatment in cavitary pulmonary aspergillosis?
What development phase is treatment in cavitary pulmonary aspergillosis in?
What are the side effects of treatment in cavitary pulmonary aspergillosis?
Related
- Manufacturer: Post Graduate Institute of Medical Education and Research, Chandigarh — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Cavitary pulmonary aspergillosis
- Compare: treatment in cavitary pulmonary aspergillosis vs similar drugs
- Pricing: treatment in cavitary pulmonary aspergillosis cost, discount & access